Australia markets close in 4 hours 25 minutes

4D pharma plc (LBPS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.53+0.07 (+0.74%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.46
Open9.62
Bid9.37 x 800
Ask11.80 x 1000
Day's range9.53 - 9.80
52-week range8.97 - 15.50
Volume22,451
Avg. volume16,671
Market cap214.783M
Beta (5Y monthly)2.82
PE ratio (TTM)N/A
EPS (TTM)-2.14
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est37.50
  • Business Wire

    4D pharma Announces $30 Million Credit Facility with Oxford Finance

    LEEDS, England, July 29, 2021--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the closing of a senior secured credit facility for up to $30m with Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies.

  • Business Wire

    4D pharma Announces Passing of Chief Financial Officer John Beck

    LEEDS, England, July 26, 2021--4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announces with great sadness that John Beck, Chief Financial Officer of 4D pharma, has passed away.

  • Business Wire

    4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T

    LEEDS, England, July 06, 2021--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the publication of pre-clinical research relating to its second-generation immuno-oncology LBP MRx1299 improving the activity of CAR-T.